Articles From: Brink's Declares Quarterly Dividend to Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca


2014/1/16
RICHMOND, Va.
Sign-up for Brink's Declares Quarterly Dividend investment picks
2014/4/3
RICHMOND, Va.
Sign-up for Brink's First-Quarter Earnings Release and Conference Call Scheduled for April 24 investment picks
2014/1/16
RICHMOND, Va.
Sign-up for Brink's Fourth-Quarter Earnings Release and Conference Call Scheduled for January 30 investment picks
2014/1/30
GAAP EPS $.53 vs.
Sign-up for Brink's Reports Fourth-Quarter Results investment picks
GAAP EPS $.63 vs.
Sign-up for Brink's Reports Improved Third-Quarter Earnings investment picks
2013/10/10
RICHMOND, Va.
Sign-up for Brink's Third-Quarter Earnings Release and Conference Call Scheduled for October 24 investment picks
2013/11/7
RICHMOND, Va.
Sign-up for Brink's to Participate in SunTrust Robinson Humphrey Conference on November 14 investment picks
2014/2/5
RICHMOND, Va.
Sign-up for Brink's to Participate in UBS One-on-One Symposium on February 11 investment picks
2014/3/6
DALLAS , March 6, 2014 /PRNewswire/ -- Brinker International, Inc. (NYSE: EAT) announced today that Guy Constant , Executive Vice President, Chief Financial Officer and President of Global Business Development has resigned from his position effective immediately.
Sign-up for Brinker International Announces Executive Changes investment picks
2013/12/20
Chili's and Maggiano's General Managers of the Year honored alongside Above Restaurant Leader of the Year at company meeting DALLAS , Dec.
Sign-up for Brinker International Awards 5-Star Restaurant Operators with Highest Company Recognition investment picks
2014/2/6
DALLAS , Feb.
Sign-up for Brinker International Board Declares Common Dividend investment picks
2014/4/10
-- Firm Initiates Coverage on Corcept Therapeutics, Ligand Pharmaceuticals, MannKind Corporation, Opexa Therapeutics and Rexahn Pharmaceuticals --
Sign-up for Brinson Patrick Re-launches Research Department investment picks
Every Sunday through Thursday from September 9 through September 30, BRIO Tuscan Grille locations across the U.S. are helping guests to “press life’s pause button” with the Weeknights in Tuscany 3-course menu.
Sign-up for BRIO Tuscan Grille Invites Guests to Indulge in a Savory Escape: Weeknights in Tuscany 3-Course Menu, Available Sunday through Thursday for $23.95 investment picks
By Everdeen Mason Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Hepatitis C Treatment Receives FDA Breakthrough Therapy Status investment picks
2013/10/28
NEW YORK (MarketWatch) -- Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers lifted to overweight: Morgan Stanley investment picks
By Russ Britt It was hard to tell the real winners from those riding market momentum Tuesday, but Bristol-Myers Squibb seemed to stand apart from the pack as the venerable drug maker hit a 52-week high after saying it was going ahead with one of its medications on late-stage tests for lung cancer.
Sign-up for Bristol-Myers Plans Late-Stage Tests on Yervoy as Lung-Cancer Treatment investment picks
By Peter Loftus Drug maker Bristol-Myers Squibb Co.
Sign-up for Bristol-Myers Returns to Sales Growth After Plavix Patent Loss, Swings to 3rd-Quarter Profit investment picks
2013/11/13
Bristol-Myers Squibb Company (NYSE:BMY) today announced a series of related changes within its Senior Management Team.
Sign-up for Bristol-Myers Squibb Announces Changes in Senior Management Team investment picks
2014/3/3
Bristol-Myers Squibb Company today announced donations totaling $1 million in 2013 to four nonprofit organizations that support patients with cancer.
Sign-up for Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support Immuno-Oncology Education for Patients and Caregivers investment picks
2013/9/17
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-five cents ($0.35) per share on the $0.10 par value Common Stock of the corporation.
Sign-up for Bristol-Myers Squibb Announces Dividend investment picks
2014/3/3
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation.
Sign-up for Bristol-Myers Squibb Announces Dividend investment picks
2013/12/19
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of approximately three percent in the company’s quarterly dividend, beginning in the first quarter of 2014.
Sign-up for Bristol-Myers Squibb Announces Dividend Increase investment picks
2013/9/27
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a pooled analysis of survival data for 12 studies (n=1,861) in patients with metastatic or locally advanced or unresectable melanoma who were treated with Yervoy ® (ipilimumab) at different doses and regimens.
Sign-up for Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy® (ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma investment picks
2014/2/3
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its global diabetes business to AstraZeneca.
Sign-up for Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Brink's Declares Quarterly Dividend to Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity